Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)

Noam Pondé^{1,2} · Dominique Agbor-Tarh³ · Lissandra Dal Lago² · Larissa A. Korde⁴ · Florentine Hilbers⁵ · Christian Jackisch⁶ · Olena Werner⁷ · Richard D. Gelber^{8,9} · Aminah Jatoi¹⁰ · Amylou C. Dueck¹¹ · Alvaro Moreno-Aspitia¹² · Christos Sotiriou² · Evandro de Azambuja² · Martine Piccart¹³

Published online: 8 October 2021

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Correction to:

Breast Cancer Research and Treatment
(2021) 185:107–116

<https://doi.org/10.1007/s10549-020-05915-9>

The ALTTO Trial, as well as this subanalysis, has been funded NIH grant (U10 CA180821), GSK and Novartis.

In the original publication of the article, the funding information was published incorrectly. Now the same has been corrected and published here.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10549-020-05915-9>.

✉ Noam Pondé
noam.ponde@accamargo.org.br

- ¹ AC Camargo Cancer Center, Rua Pires da Mota, São Paulo 1167, Brazil
- ² Institut Jules Bordet, Brussels, Belgium
- ³ Frontier Science Scotland (FSS), Kincaig, UK
- ⁴ National Cancer Institute, Bethesda, MD, USA
- ⁵ Breast International Group, Brussels, Belgium
- ⁶ Sana Klinikum, Offenbach, Germany

- ⁷ Novartis, Basel-City, Switzerland
- ⁸ Dana-Farber Cancer Institute, Boston, USA
- ⁹ Frontier Science and Technology Research Foundation, Boston, MA, USA
- ¹⁰ Mayo Clinic, Rochester, MN, USA
- ¹¹ Mayo Clinic, Scottsdale, AZ, USA
- ¹² Mayo Clinic, Jacksonville, FL, USA
- ¹³ Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium